Cancer Research and Treatment

Original Articles

Gastrointestinal cancer

Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year: Youngun Kim, Jung Sun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon; Cancer Res Treat. 2024;56(4):1231-1239. Published online May 27, 2024; DOI: https://doi.org/10.4143/crt.2024.237

Abstract PDF Supplementary Material PubReader ePub: Purpose
Since 2020, atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical characteristics and effects of Ate/Bev for over 1 year.
Materials and Methods
This study included patients with unresectable HCC treated with first-line Ate/Bev between May 2020 and April 2022. Those receiving Ate/Bev for 1 year or more were classified as the long-term treatment group.
Results
Of 246 patients, 69 (28.0%) were in the long-term treatment group, which comprised more proportions of intrahepatic tumor burden < 25%, Eastern Cooperative Oncology Group 0, and a lower proportion of portal vein tumor thrombosis than the short-term treatment group. The long-term treatment group had a higher incidence of atezolizumab-related thyroid dysfunction (31.9% vs. 10.7%, p < 0.001; median time to onset [mTTO], 2.8 months), dermatologic toxicity (29.0% vs. 14.7%, p=0.017; mTTO, 3.3 months), bevacizumab-related hypertension (44.9% vs. 22.0%, p=0.001; mTTO, 4.2 months), and proteinuria (69.6% vs. 38.4%, p < 0.001; mTTO, 6.8 months), compared to the short-term treatment group. Regarding liver function in the long-term treatment group, patients initially classified as Child-Pugh class A decreased from 87.0% to 75.4%, and albumin-bilirubin grade 1 decreased from 68.1% to 50.7% after 1 year of treatment.
Conclusion
The Ate/Bev long-term treatment group had a lower intrahepatic tumor burden, less portal vein tumor thrombosis, and better performance status and liver function at baseline. Atezolizumab-related immunological adverse events emerged relatively early in treatment compared to the bevacizumab-related. Additionally, some patients demonstrated liver function deterioration during long-term Ate/Bev treatment.

1,760 View
139 Download

Lung and Thoracic cancer

Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias: Ying Yu, Ning Chen, Sizhe Yu, Wanji Shen, Wanchen Zhai, Hui Li, Yun Fan; Cancer Res Treat. 2024;56(3):751-764. Published online January 2, 2024; DOI: https://doi.org/10.4143/crt.2023.1118

Abstract PDF Supplementary Material PubReader ePub

Purpose
The association between immune-related adverse events (irAEs) and survival outcomes in non–small cell lung cancer (NSCLC) patients treated with programmed death-(ligand) 1 [PD-(L)1] inhibitors remains controversial, partly due to variations in dealing with immortal-time bias (ITB).
Materials and Methods
We retrospectively enrolled 425 advanced NSCLC patients who received anti–PD-(L)1 monotherapy between January 2016 and June 2021, stratifying them into irAE (n=127) and non-irAE (n=298) groups. The primary endpoint was to assess the impact of irAEs on progression-free survival (PFS) and overall survival (OS). Landmark (2-, 3-, 6-, and 9-month) and time-dependent Cox analyses were performed to eliminate ITB.
Results
With a median follow-up of 38.8 months, the occurrence of overall irAEs was significantly associated with superior PFS (11.2 vs. 3.4 months, p < 0.001) and OS (31.4 vs. 14.0 months, p < 0.001), which persisted in landmark and time-dependent Cox analyses. For the main organ-specific irAEs, skin, thyroid, and hepatic irAEs, respectively, showed significantly improved survival compared to the non-irAE group, whereas pneumonitis did not. Single-organ irAEs had the best outcomes compared with multi-organ or no irAE, which also held across subgroups of skin, thyroid, and hepatic irAEs. Moreover, severe grade irAEs and immunotherapy discontinuation had a detrimental effect on survival, systemic steroid therapy showed little effect, while immunotherapy resumption had tolerable safety and a trend of improved survival.
Conclusion
After adequately adjusting ITB, the occurrence of overall irAEs predicts for favorable efficacy of anti–PD-(L)1 monotherapy in NSCLC, with better outcomes observed in patients with skin, thyroid, or hepatic irAEs, particularly those with single-organ involvement.

Citations

Citations to this article as recorded by

Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors
Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima
Nature Reviews Endocrinology.2025;[Epub] CrossRef
Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction
Koji Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Koki Otake, Masahiko Ando, Tomoko Handa, Takashi Miyata, Mariko Sugiyama, Takeshi Onoue, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Megumi Inoue, Makoto Ishii, Hiroshi Arima, Shintaro Iw
Frontiers in Endocrinology.2024;[Epub] CrossRef
Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy
Yusuke Inoue, Naoki Inui
Internal Medicine.2024;[Epub] CrossRef
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
Tianhang Zhang, Haitao Lv, Jiasong Li, Shasha Zhang, Jingjing Zhang, Siqi Wang, Yingnan Wang, Zhanjun Guo
Frontiers in Immunology.2024;[Epub] CrossRef

3,589 View
165 Download
5 Web of Science
4 Crossref

Gastrointestinal cancer

First-in-Human Phase 1 Study of a B Cell– and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer: Minkyu Jung, Jii Bum Lee, Hyo Song Kim, Woo Sun Kwon, Hyun Ok Kim, Sinyoung Kim, Myunghwan Park, Wuhyun Kim, Ki-Young Choi, Taegwon Oh, Chang-Yuil Kang, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2024;56(1):208-218. Published online June 28, 2023; DOI: https://doi.org/10.4143/crt.2022.1328

Abstract PDF Supplementary Material PubReader ePub

Purpose
BVAC-B is an autologous B cell– and monocyte-based immunotherapeutic vaccine that contains cells transfected with a recombinant human epidermal growth factor receptor 2 (HER2) gene and loaded with the natural killer T cell ligand alpha-galactosylceramide. Here, we report the first BVAC-B study in patients with HER2-positive advanced gastric cancer.
Materials and Methods
Patients with advanced gastric cancer refractory to standard treatment with HER2+ immunohistochemistry ≥ 1 were eligible for treatment. Patients were administered low (2.5×10⁷ cells/dose), medium (5.0×10⁷ cells/dose), or high dose (1.0×10⁸ cells/dose) of BVAC-B intravenously four times every 4 weeks. Primary endpoints included safety and maximum tolerated BVAC-B dose. Secondary endpoints included preliminary clinical efficacy and BVAC-B-induced immune responses.
Results
Eight patients were treated with BVAC-B at low (n=1), medium (n=1), and high doses (n=6). No dose-limiting toxicity was observed, while treatment-related adverse events (TRAEs) were observed in patients treated with medium and high doses. The most common TRAEs were grade 1 (n=2) and grade 2 (n=2) fever. Out of the six patients treated with high-dose BVAC-B, three had stable disease with no response. Interferon gamma, tumor necrosis factor-α, and interleukin-6 increased after BVAC-B treatment in all patients with medium and high dose, and HER2-specific antibody was detected in some patients.
Conclusion
BVAC-B monotherapy had a safe toxicity profile with limited clinical activity; however, it activated immune cells in heavily pretreated patients with HER2-positive gastric cancer. Earlier treatment with BVAC-B and combination therapy is warranted for evaluation of clinical efficacy.

Citations

Citations to this article as recorded by

Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights
Yu Aoki, Izuma Nakayama, Kohei Shitara
Current Oncology Reports.2025; 27(1): 15. CrossRef
Nanoparticles, a promising treatment for gastric cancer
Di Hua, Xiexing Wu, Zebin Wu, Chunyang Fan, Jiale Wang, Wei He, Yongkang Deng, Yao Zhang, Hengxiang Shu, Meng Shen, Dechun Geng, Kai Chen
Smart Materials in Medicine.2025;[Epub] CrossRef
HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
Magdalena K. Scheck, Ralf D. Hofheinz, Sylvie Lorenzen
Cancers.2024; 16(7): 1336. CrossRef
Comparative Analysis of ICIs, CAR-T Therapy, and Cancer Vaccines in Immunotherapy
Junyi Chen, Ansong Liu, Yao Yao
Transactions on Materials, Biotechnology and Life Sciences.2024; 7: 402. CrossRef

3,478 View
198 Download
2 Web of Science
4 Crossref

Breast cancer

Health-Seeking Behavior Returning to Normalcy Overcoming COVID-19 Threat in Breast Cancer: Eun-Gyeong Lee, Yireh Han, Dong-Eun Lee, Hyeong-Gon Moon, Hyoung Won Koh, Eun-Kyu Kim, So-Youn Jung; Cancer Res Treat. 2023;55(4):1222-1230. Published online April 3, 2023; DOI: https://doi.org/10.4143/crt.2023.364

Abstract PDF Supplementary Material PubReader ePub: Purpose
The coronavirus disease 2019 (COVID-19) outbreak has significantly impacted the diagnosis and treatment of breast cancer. Our study investigated the change in diagnosis and treatment of breast cancer with the progress of COVID-19 pandemic.
Materials and Methods
The study group comprised 6,514 recently diagnosed breast cancer patients between January 1, 2019, and February 28, 2021. The patients were divided into two groups: pre–COVID-19 period (3,182; January 2019 to December 2019) and COVID-19 pandemic period (3,332; January 2020 to February 2021). Clinicopathological information related to the first treatment after breast cancer diagnosis was retrospectively collected and analyzed in the two groups.
Results
Among the 6,514 breast cancer patients, 3,182 were in the pre–COVID-19 period and 3,332 were in the COVID-19 pandemic period. According to our evaluation, the least breast cancer diagnosis (21.8%) was seen in the first quarter of 2020. The diagnosis increased gradually except for the fourth quarter in 2020. While early-stage breast cancer was diagnosed 1,601 (48.1%) during the COVID-19 pandemic (p=0.001), the number of surgical treatments increased 4.6% (p < 0.001), and the treatment time was slightly shorter 2 days (p=0.001). The breast cancer subtype distribution was not statistically different between the pre–COVID-19 and COVID-19 period groups.
Conclusion
In the early stages of the pandemic, the number of breast cancer cases temporarily decreased; however, they stabilized soon, and no significant differences could be identified in the diagnosis and treatment when compared to the period before the pandemic.

2,859 View
166 Download

Gastrointestinal cancer

First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017: Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sang-Jae Park, Young-Joo Won, Sun-Whe Kim; Cancer Res Treat. 2022;54(1):208-217. Published online May 21, 2021; DOI: https://doi.org/10.4143/crt.2021.421

Abstract PDF PubReader ePub

Purpose
Hospital-based clinical studies have limitations in holistic assessment of cancer treatment and prognosis, as they omit out-of-hospital patients including elderly individuals. This study aimed to investigate trends in initial treatment and corresponding prognosis of patients with exocrine pancreatic cancer (EPC) in Korea.
Materials and Methods
The Korea Central Cancer Registry data of patients with EPC from 2006 to 2017 were retrospectively reviewed. We defined the first course of treatment (FT) as the cancer-directed treatment administered within four months after cancer diagnosis according to Surveillance, Epidemiology, and End Results (SEER) program.
Results
Among 62,209 patients with EPC, localized and regional (LR) SEER stage; patients over 70 years old; and ductal adenocarcinoma excluding cystic or mucinous (DAC) accounted for 40.6%, 50.1%, and 95.9%, respectively. “No active treatment” (NT, 46.5%) was the most frequent, followed by non-surgical FT (28.7%) and surgical FT (22.0%). Among 25,198 patients with LR EPC, surgical FT increased (35.9% to 46.3%) and NT decreased (45.0% to 29.5%) from 2006 to 2017. The rate of surgical FT was inversely related to age (55.1% [< 70 years], 37.3% [70-79 years], 10.9% [≥ 80 years]). Five-year relative survival rates of LR DAC were higher after surgical FT than after NT in localized (46.1% vs. 12.9%) and regional stage (23.6% vs. 4.9%) from 2012 to 2017.
Conclusion
Less than half of overall patients with LR EPC underwent surgical FT, and this proportion decreased significantly in elderly individuals. Clinicians should focus attention on elderly patients with EPC to provide appropriate medical advice.

Citations

Citations to this article as recorded by

Conditional Relative Survival of Exocrine Pancreatic Cancer: A Population-Based Study
Mee Joo Kang, Johyun Ha, Hyeong Min Park, Sang-Jae Park, Kyu-Won Jung, Sung-Sik Han
Annals of Surgical Oncology.2024; 31(2): 1178. CrossRef
Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study
Sujeong Shin, Won Sohn, Yoosoo Chang, Yoosun Cho, Min‐Jung Kwon, Sarah H. Wild, Christopher D. Byrne, Seungho Ryu
Hepatology Research.2024; 54(6): 551. CrossRef
Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment
Huijuan Mu, Xing Yang, Yanxia Li, Bingzheng Zhou, Li Liu, Minmin Zhang, Qihao Wang, Qian Chen, Lingjun Yan, Wei Sun, Guowei Pan
Frontiers in Oncology.2024;[Epub] CrossRef
Epidemiological trends and factors associated with survival in patients with medulloblastoma: A 45-year population-based retrospective study
Dongjie He, Yahui Yang, Peiwen Wu, Siying Zhu, Hao Chang, Chao Zhang, Qiuju Shao, Zongyan Yu
Journal of Clinical Neuroscience.2024; 126: 154. CrossRef
Surgical management for elderly patients with pancreatic cancer
Sun-Whe Kim
Annals of Surgical Treatment and Research.2023; 105(2): 63. CrossRef
Exocrine pancreatic cancer as a second primary malignancy: A population-based study
Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sung Chun Cho, Sang-Jae Park, Sun-Whe Kim, Young-Joo Won
Annals of Hepato-Biliary-Pancreatic Surgery.2023; 27(4): 415. CrossRef
Distinct prognosis of biliary tract cancer according to tumor location, stage, and treatment: a population-based study
Mee Joo Kang, Jiwon Lim, Sung-Sik Han, Hyeong Min Park, Sun-Whe Kim, Woo Jin Lee, Sang Myung Woo, Tae Hyun Kim, Young-Joo Won, Sang-Jae Park
Scientific Reports.2022;[Epub] CrossRef
Trend Analysis and Prediction of Hepatobiliary Pancreatic Cancer Incidence and Mortality in Korea
Hyeong Min Park, Young-Joo Won, Mee Joo Kang, Sang-Jae Park, Sun-Whe Kim, Kyu-Won Jung, Sung-Sik Han
Journal of Korean Medical Science.2022;[Epub] CrossRef
Epidemiology of Gastric Cancer in Korea: Trends in Incidence and Survival Based on Korea Central Cancer Registry Data (1999–2019)
Sin Hye Park, Mee Joo Kang, E Hwa Yun, Kyu-Won Jung
Journal of Gastric Cancer.2022; 22(3): 160. CrossRef
Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019
Mee Joo Kang, E Hwa Yun, Kyu-Won Jung, Sang-Jae Park
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 220. CrossRef
Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019
Sung Yeon Hong, Mee Joo Kang, Taegyu Kim, Kyu-Won Jung, Bong-Wan Kim
Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(3): 211. CrossRef

5,964 View
116 Download
11 Web of Science
11 Crossref

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer: Ah-Rong Nam, Ji-Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Do-Youn Oh, Yung-Jue Bang; Cancer Res Treat. 2019;51(3):886-900. Published online October 1, 2018; DOI: https://doi.org/10.4143/crt.2018.375

Abstract PDF Supplementary Material PubReader ePub

Purpose
Jab1 is a coactivator of c-Jun that enhances the transcriptional function of c-Jun. Jab1 is frequently overexpressed in various cancers and is associatedwith poor prognosis of cancer patients. Thus, Jab1 could be a potential therapeutic target in cancer. However, the role of Jab1 in biliary tract cancer (BTC) has not been studied.
Materials and Methods
We performed in vitro and in vivo experiments to evaluate the therapeutic potential ofJab1 inhibition in BTC.
Results
Among 8 BTC cell lines, many showed higher Jab1 expression levels. In addition, Jab1 silencing by siRNA increased p27 expression levels. SNU478 and HuCCT-1 cells exhibited profound Jab1 knockdown and increased p27 expression by Jab1-specific siRNA transfection. Jab1 silencing induced anti-proliferative and anti-migratory effects and resulted in G1 cell cycle arrest in SNU478 and HuCCT-1 cells. In addition, Jab1 silencing potentiated the anti-proliferative and anti-migratory effects of cisplatin by increasing DNA damage. Interestingly,Jab1 knockdown increased PTEN protein half-life, resulting in increased PTEN expression. In the HuCCT-1 mouse xenograft model, stable knockdown of Jab1 by shRNA also showed anti-proliferative effects in vivo, with decreased Ki-67 expression and AKT phosphorylation and increased Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling and p27 expression.
Conclusion
Jab1 knockdown demonstrated anti-proliferative and anti-migratory effects in BTC cells by increasing DNA damage and stabilizing PTEN, resulting in G1 cell cycle arrest. In addition, Jab1 silencing potentiated the anti-proliferative effects of cisplatin. Our data suggest that Jab1 may be a potential therapeutic target in BTC that is worthy of further investigations.

Citations

Citations to this article as recorded by

COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma
Jiahui Liu, Dexing Han, Junfeng Xuan, Jinye Xie, Weijia Wang, Quan Zhou, Kang Chen
Aging.2024; 16(6): 5264. CrossRef
Pan-cancer analyses of Jab1/COPS5 reveal oncogenic role and clinical outcome in human cancer
Liping Wang, Xiaojiao Zeng, Gui Yang, Guohong Liu, Yunbao Pan
Heliyon.2022; 8(12): e12553. CrossRef
Jab1/Cops5: a promising target for cancer diagnosis and therapy
Chunjue Yuan, Dong Wang, Guohong Liu, Yunbao Pan
International Journal of Clinical Oncology.2021; 26(7): 1159. CrossRef

8,604 View
225 Download
6 Web of Science
3 Crossref

The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study: Jaewon Lee, Jin Lim, Jong Seo Park, Miso Kim, Tae-Yong Kim, Tae Min Kim, Kyung-Hun Lee, Bhumsuk Keam, Sae-Won Han, Je-Ho Mun, Kwang Hyun Cho, Seong Jin Jo; Cancer Res Treat. 2018;50(4):1186-1193. Published online December 14, 2017; DOI: https://doi.org/10.4143/crt.2017.435

Abstract PDF Supplementary Material PubReader ePub

Purpose
Patients treated with anticancer agents often experience a variety of treatment-related skin problems, which can impair their quality of life.
Materials and Methods
In this cross-sectional study, Dermatology Life Quality Index (DLQI) and clinical information were evaluated in patients under active anticancer treatment using a questionnaire survey and their medical records review.
Results
Of 375 evaluated subjects with anticancer therapy, 136 (36.27%) and 114 (30.40%) were treated for breast cancer and colorectal cancer, respectively. We found that women, breast cancer, targeted agent use, and longer duration of anticancer therapy were associated with higher dermatology-specific quality of life distraction. In addition, itching, dry skin, easy bruising, pigmentation, papulopustules on face, periungual inflammation, nail changes, and palmoplantar lesions were associated with significantly higher DLQI scores. Periungual inflammation and palmoplantar lesions scored the highest DLQI.
Conclusion
We believe our findings can be helpful to clinicians in counseling and managing the patients undergoing anticancer therapy.

Citations

Citations to this article as recorded by

The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Annika Belzer, Jolanta J. Pach, Kailyn Valido, Jonathan S. Leventhal
American Journal of Clinical Dermatology.2024; 25(3): 435. CrossRef
Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy
Maria Mannino, Pietro Sollena, Alessandro Di Stefani, Ernesto Rossi, Ettore D’Argento, Giovanni Schinzari, Giampaolo Tortora, Ketty Peris
Dermatology.2024; 240(4): 523. CrossRef
A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country
Areesha Abid, Humza Saeed, Uswa Iftikhar, Muhammad Khubaib Arshad, Muhammad Uzair Shahid, Tayyab Rasool, Faizan Fazal, Aman Goyal, Anum Akbar
Journal of Oncology Pharmacy Practice.2024;[Epub] CrossRef
Chemotherapy induced alopecia in breast cancer patients: A monocentric prospective study
Wala Ben Kridis, Olfa Boudawara, Afef Khanfir
Breast Disease.2024; 43(1): 251. CrossRef
Impact of Xerosis in Patients With Cancer Receiving Epidermal Growth Factor Receptor or Mitogen-Activated Protein Kinase Inhibitors: ATIXI, A Non-Interventional, Prospective, Pilot Study
Pietro Quaglino, Giuseppe Argenziano, Emi Dika, Michela Starace, Simone Amabile, Paolo Fava, Elvira Moscarella, Bianca Maria Piraccini, Alain Delarue, Olivia Dialla, Fabienne Zumaglini, Giampiero Girolomoni
Dermatology Practical & Conceptual.2024; 14(4): e2024259. CrossRef
Global trends in adolescent and young adult female cancer burden, 1990-2021: insights from the Global Burden of Disease study
Z. Huang, J. Wang, H. Liu, B. Wang, M. Qi, Z. Lyu, H. Liu
ESMO Open.2024; 9(11): 103958. CrossRef
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer
Maham Ahmad, Sabrina Saeed, Brianna Olamiju, Andrea Silber, Jonathan Leventhal
International Journal of Women’s Dermatology.2023; 9(1): e073. CrossRef
Aloe vera gel for prevention of chemotherapy-induced hyperpigmentation: Four case reports
Chia-Chi Chiu, Yi-Wen Hsiao, Yu-Chuan Wen, Tsung-Yen Chang, Shih-Hsiang Chen, Tang-Her Jaing
Medicine.2023; 102(25): e34037. CrossRef
Skin-related Quality of Life in Patients with Lung Cancer Taking Oral Targeted Agents: A Single-Center, Cross-Sectional Study
Joo Mi Park, Jeong Hye Kim
Asian Oncology Nursing.2023; 23(2): 84. CrossRef
Dermatological Side Effects of Cancer Treatment: Psychosocial Implications—A Systematic Review of the Literature
Vera Almeida, Daniela Pires, Marta Silva, Maribel Teixeira, Ricardo João Teixeira, André Louro, Maria Alzira Pimenta Dinis, Maria Ferreira, Ana Teixeira
Healthcare.2023; 11(19): 2621. CrossRef
The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
Brigitte Dreno, Kiarash Khosrotehrani, Giselle De Barros Silva, Julie Ryan Wolf, Delphine Kerob, Mark Trombetta, Etienne Atenguena, Pascale Dielenseger, Meng Pan, Florian Scotte, Ivan Krakowski, Mario Lacouture
Supportive Care in Cancer.2023;[Epub] CrossRef
Effectiveness and Tolerability of Natural Herbal Formulations in the Prevention of Radiation-Induced Skin Toxicity in Patients Undergoing Radiotherapy
Georgios Koukourakis, Georgios Pissakas, Christos G. Ganos, Gregory Sivolapenko, Dimitrios Kardamakis
The International Journal of Lower Extremity Wounds.2022; 21(1): 75. CrossRef
Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes
Jang‐Hee Oh, Woojune Hur, Na Li, Seong Jin Jo
Experimental Dermatology.2022; 31(6): 918. CrossRef
An Emollient PLUS Balm Is Useful for the Management of Xerosis in Patients Treated for Cancer: A Real-World, Prospective, Observational, Multicenter Study
Véronique Vendrely, Ander Mayor-Ibarguren, Aline Stennevin, Ariadna Ortiz-Brugués
Dermatology and Therapy.2022; 12(3): 683. CrossRef
Nail pigmentation induced by chemotherapy: an observational study of patients with early-stage breast cancer
Kuikui Jiang, Simei Shi, Qiulian Lin, Peng Sun, Luan Zhang, Zhongyu Yuan, Ruoxi Hong, Yanxia Shi, Xia Liu, Jingmin Zhang, Jiajia Huang, Xiwen Bi, Wen Xia, Qianyi Lu, Qiufan Zheng, Shusen Wang, Fei Xu
Holistic Integrative Oncology.2022;[Epub] CrossRef
Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new
Hae‐Jin Suh, Ángeles Flórez, Víctor Sacristán, Ángeles Rodríguez Martinez, Francisca Fernández, Lucía Vilanova‐Trillo, Manuel Constenla, Manuel Pereiro
International Journal of Dermatology.2021; 60(2): 208. CrossRef
The Impact of Acne, Atopic Dermatitis, Skin Toxicities and Scars on Quality of Life and the Importance of a Holistic Treatment Approach
Brigitte Dreno, Jean Michel Amici, Ann Laure Demessant-Flavigny, Charlotte Wright, Charles Taieb, Seemal R Desai, Andrew Alexis
Clinical, Cosmetic and Investigational Dermatology.2021; Volume 14: 623. CrossRef
Evaluating health related quality of life in outpatients receiving anti-cancer treatment: results from an observational, cross-sectional study
Hae-Jin Suh Oh, Ángeles Flórez Menéndez, Víctor Sacristán Santos, Ángeles Rodríguez Martínez, Francisca Fernández Ribeiro, Lucía Vilanova-Trillo, Manuel Constenla Figueiras, Manuel Pereiro Ferreiros
Health and Quality of Life Outcomes.2021;[Epub] CrossRef
Dermatologic conditions in women receiving systemic cancer therapy
Michelle N. Ferreira, Julie Y. Ramseier, Jonathan S. Leventhal
International Journal of Women's Dermatology.2019; 5(5): 285. CrossRef

8,483 View
213 Download
21 Web of Science
19 Crossref

Body Composition Predicts Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: Neehar D. Parikh, Peng Zhang, Amit G. Singal, Brian A. Derstine, Venkat Krishnamurthy, Pranab Barman, Akbar K. Waljee, Grace L. Su; Cancer Res Treat. 2018;50(2):530-537. Published online June 1, 2017; DOI: https://doi.org/10.4143/crt.2017.156

Abstract PDF Supplementary Material PubReader ePub

Purpose
The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is often uncertain. We aimed to utilize analytic morphomics, a high-throughput imaging analysis, to assess if body composition is predictive of post-TACE survival.
Materials and Methods
We included patients from a single center (Ann Arbor VA)who had TACE as the primary treatment forHCC and had a pre-treatment computed tomography scans. Univariate analysis and multivariate conditional inference tree analysis were utilized to identify the morphomic characteristics predictive of 1-year survival. Resultswere validated in an external cohort(University of MichiganHealth System) ofHCC patientswho underwent TACE as their primary treatment.
Results
In the 75 patients in the derivation cohort, median survival was 439 (interquartile range, 377 to 685) days from receipt of TACE, with 1-year survival of 61%. Visceral fat density (VFD) was the only morphomic factor predictive of overall and 1-year survival (p < 0.001). Patients with VFD above the 56th percentile had a 1-year survival of 39% versus 78% for those below the 56th percentile. VFD also correlated with 1-year survival in the external validation cohort (44% vs. 72%, p < 0.001). In a secondary analysis, patients with higher VFD were significantly more likely to experience hepatic decompensation after TACE (p < 0.001).
Conclusion
VFD served as an objective predictor of mortality in patients undergoing TACE, possibly through its ability to predict hepatic decompensation. VFD may serve as a radiographic biomarker in predicting TACE outcomes.

Citations

Citations to this article as recorded by

Impact of body composition on the prognosis of hepatocellular carcinoma patients treated with transarterial chemoembolization: A systematic review and meta-analysis
Anrong Wang, Junfeng Li, Changfeng Li, Hui Zhang, Yingfang Fan, Kuansheng Ma, Qiang Wang
Heliyon.2024; 10(3): e25237. CrossRef
Incorporation of quantitative imaging data using artificial intelligence improves risk prediction in veterans with liver disease
Grace L. Su, Peng Zhang, Patrick X. Belancourt, Bradley Youles, Binu Enchakalody, Ponni Perumalswami, Akbar Waljee, Sameer Saini
Hepatology.2024; 80(4): 928. CrossRef
Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer
Valerie Gunchick, Edward Brown, Juan Liu, Jason W. Locasale, Philip A. Philip, Stewart C. Wang, Grace L. Su, Vaibhav Sahai
JAMA Network Open.2024; 7(10): e2440047. CrossRef
Role of tumor-specific and whole-body imaging biomarkers for prediction of recurrence in patients with stage III colorectal cancer
Amir A. Borhani, Peng Zhang, Brenda Diergaarde, Sophie Darwiche, Kalina Chuperlovska, Stewart C. Wang, Robert E. Schoen, Grace L. Su
Abdominal Radiology.2024;[Epub] CrossRef
Artificial Intelligence and Machine Learning Predicting Transarterial Chemoembolization Outcomes: A Systematic Review
Elina En Li Cho, Michelle Law, Zhenning Yu, Jie Ning Yong, Claire Shiying Tan, En Ying Tan, Hirokazu Takahashi, Pojsakorn Danpanichkul, Benjamin Nah, Gwyneth Shook Ting Soon, Cheng Han Ng, Darren Jun Hao Tan, Yuya Seko, Toru Nakamura, Asahiro Morishita, S
Digestive Diseases and Sciences.2024;[Epub] CrossRef
Impact of sarcopenia on clinical outcomes for patients with resected hepatocellular carcinoma: a retrospective comparison of Eastern and Western cohorts
Berend R. Beumer, Kosei Takagi, Stefan Buettner, Yuzo Umeda, Takahito Yagi, Toshiyoshi Fujiwara, Jeroen L.A. van Vugt, Jan N.M. IJzermans
International Journal of Surgery.2023; 109(8): 2258. CrossRef
Clinical-radiomics predictors to identify the suitability of transarterial chemoembolization treatment in intermediate-stage hepatocellular carcinoma: A multicenter study
Dan-Dan Wang, Jin-Feng Zhang, Lin-Han Zhang, Meng Niu, Hui-Jie Jiang, Fu-Cang Jia, Shi-Ting Feng
Hepatobiliary & Pancreatic Diseases International.2023; 22(6): 594. CrossRef
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
Alexey Surov, Maximilian Thormann, Mattes Hinnerichs, Max Seidensticker, Ricarda Seidensticker, Osman Öcal, Kerstin Schütte, Christoph J. Zech, Christian Loewe, Otto van Delden, Vincent Vandecaveye, Chris Verslype, Bernhard Gebauer, Christian Sengel, Iren
Hepatology Communications.2023;[Epub] CrossRef
Adipose distribution patterns as prognostic factors in patients with HCC: A systematic review and meta-analysis
Shuo Shi, Haiyan Yi, Yi Zheng, Yuxuan Zhao, Dexin Yu
European Journal of Radiology.2023; 167: 111025. CrossRef
Preoperative Pectoralis Muscle Index Predicts Distant Metastasis-Free Survival in Breast Cancer Patients
Wen-juan Huang, Meng-lin Zhang, Wen Wang, Qing-chun Jia, Jia-rui Yuan, Xin Zhang, Shuang Fu, Yu-xi Liu, Shi-di Miao, Rui-tao Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Metabolic abnormalities, liver and body fat in American versus Chinese patients with non‐alcoholic fatty liver disease
Wei Zhang, Grace L Su, Kaza Sravanthi, Rui Huang, Yi Wang, Huiying Rao, Lai Wei, Anna S Lok
JGH Open.2022; 6(8): 519. CrossRef
Impact of muscle mass on survival of patients with hepatocellular carcinoma after liver transplantation beyond the Milan criteria
Berend R. Beumer, Jeroen L.A. van Vugt, Gonzalo Sapisochin, Peter Yoon, Marco Bongini, Di Lu, Xiao Xu, Paolo De Simone, Lorenzo Pintore, Nicolas Golse, Malgorzata Nowosad, William Bennet, Emmanouil Tsochatzis, Evangelia Koutli, Fariba Abbassi, Marco P.A.W
Journal of Cachexia, Sarcopenia and Muscle.2022; 13(5): 2373. CrossRef
Bone Densities Assessed by Hounsfield Units at L5 in Computed Tomography Image Independently Predict Hepatocellular Carcinoma Development in Cirrhotic Patients
Christopher Yeh, Ming-Wei Lai, Chau-Ting Yeh, Yang-Hsiang Lin, Jeng-Hwei Tseng
Journal of Clinical Medicine.2022; 11(19): 5562. CrossRef
What Is the Role of Body Composition Assessment in HCC Management?
Pompilia Radu, Maryam Ebadi, Aldo J. Montano-Loza, Jean Francois Dufour
Cancers.2022; 14(21): 5290. CrossRef
High subcutaneous adipose tissue density correlates negatively with survival in patients with hepatocellular carcinoma
Leona von Hessen, Marie Roumet, Martin Helmut Maurer, Naomi Lange, Helen Reeves, Jean‐François Dufour, Pompilia Radu
Liver International.2021; 41(4): 828. CrossRef
Automated Measurements of Body Composition in Abdominal CT Scans Using Artificial Intelligence Can Predict Mortality in Patients With Cirrhosis
Winnie Y. Zou, Binu E. Enchakalody, Peng Zhang, Nidhi Shah, Sameer D. Saini, Nicholas C. Wang, Stewart C. Wang, Grace L. Su
Hepatology Communications.2021; 5(11): 1901. CrossRef
The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
Jihye Lim, Kyung Won Kim, Yousun Ko, Il-Young Jang, Yung Sang Lee, Young-Hwa Chung, Han Chu Lee, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Jonggi Choi, Danbi Lee
BMC Cancer.2021;[Epub] CrossRef
Morphomic Signatures Derived from Computed Tomography Predict Hepatocellular Carcinoma Occurrence in Cirrhotic Patients
Kung-Hao Liang, Peng Zhang, Chih-Lang Lin, Stewart C. Wang, Tsung-Hui Hu, Chau-Ting Yeh, Grace L. Su
Digestive Diseases and Sciences.2020; 65(7): 2130. CrossRef
Visceral Adipose Tissue Radiodensity Is Linked to Prognosis in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy
Maryam Ebadi, Carlos Moctezuma-Velazquez, Judith Meza-Junco, Vickie E. Baracos, Abha R. DunichandHoedl, Sunita Ghosh, Philippe Sarlieve, Richard J. Owen, Norman Kneteman, Aldo J. Montano-Loza
Cancers.2020; 12(2): 356. CrossRef
Review article: prognostic significance of body composition abnormalities in patients with cirrhosis
Maryam Ebadi, Rahima A. Bhanji, Puneeta Tandon, Vera Mazurak, Vickie E. Baracos, Aldo J. Montano‐Loza
Alimentary Pharmacology & Therapeutics.2020; 52(4): 600. CrossRef
Sarcopenia Severity Based on Computed Tomography Image Analysis in Patients with Cirrhosis
Maryam Ebadi, Rahima A. Bhanji, Abha R. Dunichand-Hoedl, Vera C. Mazurak, Vickie E. Baracos, Aldo J. Montano-Loza
Nutrients.2020; 12(11): 3463. CrossRef
Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis
Wei Zhang, Rui Huang, Yi Wang, Huiying Rao, Lai Wei, Grace L. Su, Anna S. Lok
Hepatology Communications.2019; 3(12): 1585. CrossRef
Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics
Jonghoon Kim, Seung Joon Choi, Seung-Hak Lee, Ho Yun Lee, Hyunjin Park
American Journal of Roentgenology.2018; 211(5): 1026. CrossRef
Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer
Joanne Marie O’Rourke, Vandana Mridhu Sagar, Tahir Shah, Shishir Shetty
World Journal of Gastroenterology.2018; 24(39): 4436. CrossRef
The Adverse Impact of Sarcopenia and Visceral Fat Deposition on the Course of Hepatocellular Carcinoma and the Role of Nutritional Interventions
Adam McCulloch, Hardip Malhi, Amritpal Dhaliwal, Sheldon Cooper, Tahir Shah
European Medical Journal.2018; : 126. CrossRef

10,630 View
224 Download
25 Web of Science
25 Crossref

Changes in Arterioportal Shunts in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis Who Were Treated with Chemoembolization Followed by Radiotherapy: Dongryul Oh, Sung Wook Shin, Hee Chul Park, Sung Ki Cho, Do Hoon Lim, Seung Woon Paik; Cancer Res Treat. 2015;47(2):251-258. Published online October 27, 2014; DOI: https://doi.org/10.4143/crt.2014.011

Abstract PDF PubReader ePub

Purpose
In this study, we retrospectively investigated the prevalence of arterioportal (AP) shunts in hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) and evaluated the changes in AP shunts after chemoembolization followed by external beam radiation therapy (EBRT).
Materials and Methods
We analyzed 54 HCC patients with PVTT who were treated with chemoembolization followed by EBRT. EBRT was uniformly delivered at a total dose of 30 to 45 Gy (median, 35 Gy), with a daily dose of 2 to 4.5 Gy. Angiographic images of chemoembolization before and after radiation therapy (RT) were reviewed to investigate the AP shunt.
Results
During the initial session of chemoembolization, 33 of 54 patients (61%) had an AP shunt. After EBRT, 32 out of 33 patients had an additional session of chemoembolization and were evaluated for a change in the AP shunt. The AP shunt decreased in 20 of 32 patients (63%) after chemoembolization followed by EBRT. The 1-year calculated overall survival (OS) rate for all patients was 52.6% and the 2-year OS was 36.4%. The median OS in all patients was 13 months. Patients with AP shunt showed poorer median OS than those without AP shunt, but there was no statistically significant difference (median, 12 months vs. 17 months).
Conclusion
The AP shunt frequently occurs in HCC patients with PVTT. This study suggests that a poor prognosis is associated with an AP shunt. Chemoembolization followed by RT may produce a decrease in AP shunts.

Citations

Citations to this article as recorded by

Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization
Wenzhe Fan, Bowen Zhu, Xinlin Zheng, Shufan Yue, Mingjian Lu, Huishuang Fan, Liangliang Qiao, Fuliang Li, Guosheng Yuan, Yanqin Wu, Xinhua Zou, Hongyu Wang, Miao Xue, Jiaping Li
Journal of Cancer Research and Clinical Oncology.2023; 149(5): 1873. CrossRef
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
Wenzhe Fan, Jian Guo, Bowen Zhu, Shutong Wang, Lei Yu, Wanchang Huang, Huishuang Fan, Fuliang Li, Yanqin Wu, Yue Zhao, Yu Wang, Miao Xue, Hongyu Wang, Jiaping Li
European Radiology.2021; 31(11): 8291. CrossRef
Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma
Ji Hyun Lee, Gyu Sang Yoo, Young Cheol Yoon, Hee Chul Park, Hyun Su Kim
Scientific Reports.2021;[Epub] CrossRef
Multidisciplinary treatment of advanced hepatocellular carcinoma with severe arterioportal shunt: a case report
Yao-chang Luo, Hai-lin Lu, Wen-ling Song, Fei-fei Xuan
Journal of International Medical Research.2021;[Epub] CrossRef
Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt
Hai-lin Lu, Fei-fei Xuan, Yao-chang Luo, Xiao Qin
Abdominal Radiology.2021; 46(11): 5417. CrossRef
Portal stent with endovascular brachytherapy improves the efficacy of TACE for hepatocellular carcinoma with main portal vein tumor thrombus
Tian Li, Chong Liu, Jin-Tong He, Kai-Da Sui, Zhou-Bo Zhang, Duo Hong, Hong-Ying Su, Hai-Bo Shao
Hepatobiliary & Pancreatic Diseases International.2020; 19(2): 187. CrossRef
Sorafenib Reduced Significantly Heptopulmonary Shunt in a Large Hepatocelullar Carcinoma
Philippe d'Abadie, Ivan Borbath, Pierre Goffette, Nadia Amini, Renaud Lhommel
Clinical Nuclear Medicine.2019; 44(1): 70. CrossRef
Hepatopulmonary shunting on Tc99m-MAA liver mapping: correlation with dynamic cross-sectional imaging and description of different shunting patterns
Mohammed Bermo, Manuela C. Matesan, Malak Itani, Fatemeh Behnia, Hubert J. Vesselle
Abdominal Radiology.2018; 43(11): 3001. CrossRef
Chemoembolisation with polyvinyl alcohol for advanced hepatocellular carcinoma with portal vein tumour thrombosis and arterioportal shunts: efficacy and prognostic factors
L. Xiao, Q. Liu, W. Zhao, H. Pang, Q. Zeng, Y. Chen, J. Zhao, Q. Mei, X. He
Clinical Radiology.2018; 73(12): 1056.e17. CrossRef
Polyvinyl alcohol terminal chemoembolization for hepatocellular carcinoma with hepatic arteriovenous shunts: Safety, efficacy, and prognostic factors
Qiu-song Liu, Que-lin Mei, Yan-hao Li
European Journal of Radiology.2017; 89: 277. CrossRef
Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients
Lidia Sancho, Macarena Rodriguez-Fraile, Jose Ignacio Bilbao, Carmen Beorlegui Arteta, Mercedes Iñarrairaegui, Veronica Moran, Bruno Sangro
Journal of Vascular and Interventional Radiology.2017; 28(11): 1536. CrossRef
Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study
Jeong Il Yu, Jae Won Park, Hee Chul Park, Sang Min Yoon, Do Hoon Lim, Joon Hyeok Lee, Han Chu Lee, Seon Woo Kim, Jong Hoon Kim
Radiotherapy and Oncology.2016; 118(2): 408. CrossRef

16,023 View
130 Download
14 Web of Science
12 Crossref

Therapeutic Outcome and Prognosis in Dlderly Patients with Non - Hodgkin's Lymphoma: Jee Sook Hahn, Jin Hyuk Choi, Seung Tae Lee, Yoo Hong Min, Yun Woong Ko; J Korean Cancer Assoc. 1999;31(2):320-330.

Abstract PDF: PURPOSE
The prognosis of non-Hodgkins lymphoma (NHL) in elderly patients seems to be poorer than that in patients aged less than 60 years. This may be due to the lower tolerance for combination chemotherapy in the elderly. Aggressive combination chemo-therapy, which is the treatment of choice in intermediate and high grade NHL of adulthood, may be associated with unpredictab1y severe and lethal toxicity and worsened quality of life in the elderly. We investigated the treatment responses, toxicities and prognostic factors of NHL in elderly patients treated with combination chemotherapy.
MATERIALS AND METHODS
We treated 116 elderly (>60 yrs) patients with NHL between January 1986 and June 1996 with adriamycin-containing regimens, such as CHOP (cyclo- phosphamide, adriamycin, vincristine, prednisolone), BACOP (bleomycin, adriamycin, cyclophosphamide, vincristine, prednisolone), and mBACOP (methotrexate, bleomycin, adriamycin, cyclophosphamide, vincristine, prednisolone). Patients in this study ranged from 60 to 81 (median 67) years of age. Fifty-five percent of patients were in stage I or II and the rest (45%) were in stage III or IV. The histologic grade was predominantly (91%) of intermediate and high grade type.
RESULTS
The treatment responses were complete (CR) in 55% and partial (PR) in 25%. The median durstion of CR was 32 (3-132) months. The CR rate was significantly higher in patients treated with RDI (relative dose intensity) > 75% than that in the patients treated with RDI < 75% (p 0.003), but there was no significant difference in CR rate between treatment regimens (p-0.38). At a median follow up of 48-months (range, 12 to 132 months), the estimated 5-year ovetall survival was 46%. Ann Arbor Stage (I, II vs III, IV), ECOG performance (0-1 vs 2-3), RDI (>75% vs <75%) and the treatment response were important prognostic factors in the univariate analysis, and the treament response (CR vs non-CR) was the only independent prognostic parameter in the multivariate analysis. The most frequent and severe toxicity associated with chemotherapy was infection with or without neutropenia. The rate of severe infection was significantly decreased in the patients supported with G/GM-CSF but not in the dose-reduction group (RDI<75% vs >75%).
CONCLUSION
Our data suggests that achievement of the CR after combination chemotherpy is the most important prognostic factor in the elderly patients with NHL. Suboptimal chemotherapy (RDI<75%) reduced the complete remission rate without reducing the likelihood of developing severe toxicities. Optimal chemotherapy with supportive cares involving the use of hematopoietic growth factors may be needed to improve the treatment response and the survival in the elderly patients with aggressive NHL.

2,731 View
17 Download

Clinical Trial of Human Recombinant Interleukin-2 ( IL-2: Joung Soon Jang, Jae Bum Jun, Joon Soo Hahm, Min Ho Lee, Il Young Choi, Te June Chung; J Korean Cancer Assoc. 1990;22(1):96-106.

Abstract PDF: The effects of immunotherapy with IL-2 were evaluated in 10 patients with advanced cancers for whom standard anticancer chemotherapy had been ineffective from Apr. 1988 to Mar. 1989. Of total 10 patients, five were treated witn 24 hr continuous IV infusion of IL-2 with the dosage of 1 x 10(4) u/kg/day or 1 x 10(5) u/kg/day respectively for 5 days and another five with intraperitoneal bolus infusion of IL-2 with the dosage of 1 x10(4) u/kg/day or 1 x 10(5) u/kg/day after removal of ascites by paracenthesis for 5 days. Of the 10 evaluable patients, 9 (90%) patients had no response and only 1 (10%) had minimal response. One patient who had minmal response had squamous cell ca of esophagus and has received IL-2 intravenously. Most common side effects were fever and chills and they could be prevented or alleviated by use of NSAIDs or IV infusion of Meperidine in severe cases. Serious side effects were capillay leak syndrome and its complication which show hypotension, generalized edema, weight gaine and azotemia. GI symptom, rigor and skin lesion were also obseved. But pulmonary edema was not observed. All of the above side effects were well overcome by conservative management. In the intraperitoneal infusion group the side effects occurred less frequently than IV infusion group. Anemia, neutropenia, eosinophilia, azotemia and abnormal liver function test were observed, but they have returned to normal range after discontinuation of IL-2 infusion. The absolute lymphocyte counts decreased I day after IV infusion of IL-2 and came back to show revound lymphocytosis from the next day after discontinuation of IL-2 infusion. They returned to pretreatment level from the 4th day of discontinuation of IL-2 infusion. In the intraperitoneal infusion group total WBC counts in ascites began to increase from 24 hrs after IL-2 infusion and reached peak at the end day of infusion. They began to decreased with discontinuation of infusion. Compared with WBC counts in ascites, those in peripheral blood showed delayed increase. In conclusion, 1 x 10' and 1 x 10 u/kg/day infusion of IL-2 were enough to increase the lymphocyte pool in vivo respectively, although no effective clinical response was obtained. There was no difference in the clinical and side effects between 1 x 10(4) and 1 x 10(5) u/kg/day infusion groups. This study warrants for further investigation into the determination of effeective therapeutic concentration of IL-2 and its route of adminstration.

2,700 View
15 Download

First
Prev
Page of 1
Next
Last

Search